Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04286386 · ClinicalTrials.gov registry record
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
A clinical trial of Prostate Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 130
- Enrollment target
- 1
- Study location
NCT04286386 is a study of Prostate Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 130 participants, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04286386, a study of Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial examines if a prostate magnetic resonance spectroscopic imaging can be performed on a 3T scanner using an investigational contrast called hyperpolarized 13-C pyruvate for the development of a clinical prostate cancer exam. 3T refers to the strength of the magnetic resonance spectroscopic imaging (MRSI) machine. MRSI is a magnetic resonance imaging (MRI) technique that can show certain chemical differences in healthy and diseased prostate tumor tissue compared to standard multiparametric MRI that may not detect the tumor. Hyperpolarized (HP) 13-C pyruvate is a contrast drug that may help the scanner see the tumor site better during imaging. Hyperpolarization of 13-C pyruvate may allow pyruvate and its metabolites to be detected upon injection, which in turn, allow the prostate cancer to be found and treated.
Conditions Studied
Interventions
- PROCEDURE Surgical Procedure
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
- OTHER Hyperpolarized Carbon C 13 Pyruvate
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2026-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04286386
The ClinicalTrials.gov registry entry for NCT04286386 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (40% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Surgical Procedure is the first listed.
NCT04286386 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04286386 about?
NCT04286386 is a clinical study titled "Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam". This trial examines if a prostate magnetic resonance spectroscopic imaging can be performed on a 3T scanner using an investigational contrast called hyperpolarized 13-C pyruvate for the development of a clinical prostate cancer exam. 3T refers to the strength of the magnetic resonance spectroscopic ...
What is the current status of trial NCT04286386?
This trial is currently active not recruiting. The enrollment target is 130 participants. The study started on 2019-12-19. Estimated completion is 2026-04-30.
What conditions does trial NCT04286386 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT04286386?
The interventions under investigation include: Surgical Procedure (PROCEDURE), Magnetic Resonance Spectroscopic Imaging (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (OTHER).
Who is sponsoring clinical trial NCT04286386?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04286386 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RECRUITING · Early Phase 1
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.